
Prafull Babu Kalyanshetti
About Prafull Babu Kalyanshetti
Data last updated:
Prafull Babu Kalyanshetti is a Designated Partner at Med Xpress Pharma India Llp (since 2016) and Director at Crecent Health Private Limited (since 2026). The companies operate in E-Commerce. The largest current company by reported revenue is Med Xpress Pharma India Llp at ₹12.47 Cr (FY 2023).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Designated Partner | 08 Mar 2016 | 2016 | ₹12.47 Cr (FY 2023) | Active | |
| Director | 15 Jul 2026 | 2026 | Active |
Board colleagues of Prafull Babu Kalyanshetti
| Name | DIN | Company | Designation |
|---|---|---|---|
| Mohammadhussain Abdulgani Rayma | 11121477 | Med Xpress Pharma India Llp | Designated Partner |
| Nitin Kakasaheb Suryavanshi | 11121495 | Med Xpress Pharma India Llp | Designated Partner |
| Swati Patil | 11573709 | Crecent Health Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Prafull Babu Kalyanshetti
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Prafull Babu Kalyanshetti
Prafull Babu Kalyanshetti currently holds 2 directorships: Med Xpress Pharma India Llp (Designated Partner, since 08 Mar 2016, revenue ₹12.47 Cr (FY 2023)); Crecent Health Private Limited (Director, since 15 Jul 2026).
Prafull Babu Kalyanshetti was first appointed on 08 Mar 2016 as Designated Partner at Med Xpress Pharma India Llp. The most recent appointment on record is 15 Jul 2026 at Crecent Health Private Limited.
The current boards of Prafull Babu Kalyanshetti's companies include Mohammadhussain Abdulgani Rayma (Med Xpress Pharma India Llp), Nitin Kakasaheb Suryavanshi (Med Xpress Pharma India Llp), Swati Patil (Crecent Health Private Limited).